Insulet announced two separate $25m deals that will expand its portfolio of automated insulin delivery intellectual property.
Massachusetts-based Insulet markets the Omnipod 5 and Omnipod DASH tubeless automated insulin delivery systems; Omnipods can be integrated with a smartphone and a continuous glucose monitor to manage blood sugar without finger sticks or daily injections
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?